PR10212_启动子库_赢润生物-中国基因研究资源库
您好,欢迎光临赢润生物技术商城
请登录    |     免费注册     帮助中心

客服热线:0731—84317068

QQ咨询:12695920

订货邮箱:service@yrgene.com

当前位置: 首页 > 启动子库

启动子产品信息

订购信息

货号 种属 载体 描述 价格 周期
PR10212 Human pcDNA3.1-EGFP 5000 5-7 周

产品参数

Gene Promoter: Endoglin
Alias: CD105
Specificity: Endothelial cells
Backbone: pDRIVE, pDRIVE5-SEAP, pGL3-basic, pcDNA3.1-EGFP, ect.

产品说明书

pDRIVE-Endoglin(human) Map 产品说明书(点击下载)

pDRIVE5-SEAP-Endoglin(human) Map 产品说明书(点击下载)

pDRIVE5-SEAP-Endoglin(human) Sequence 产品说明书(点击下载)

产品说明

Description:
Endoglin (CD105) is a transforming growth factor-beta (TGF-β) coreceptor expressed mainly on endothelial cells and preferentially in the neovasculature associated with hypoxia such as ischemic tissues and tumors. The endoglin promoter lacks consensus TATA and CAAT boxes but contains Sp1, NF-κB and TGF-β binding sites [1]. These sites are located in a -400/+341 fragment upstream of the endoglin gene which is sufficient to confer endothelial specificity. Regulation of endoglin occurs at the transcriptional level; basal endoglin transcription is highly dependent on Sp1 and is stimulated by TGF-β and hypoxia [2]. The endoglin promoter has been used to target gene expression to the vasculature in transgenic animals [3].


1. Rius C. et al., 1998. Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood. 92(12):4677-90.
2. Sanchez-Elsner T. et al., 2002. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem. 277(46):43799-808.
3. Cowan PJ. et al., 2003. Targeting gene expression to endothelium in transgenic animals: a comparison of the human ICAM-2, PECAM-1 and endoglin promoters. Xenotransplantation. 10(3):223-31.

立即购买 加入购物车

Copyright ©2014 长沙赢润生物技术有限公司版权所有 湘ICP备15013987号-2

技术支持